Summary & Overview
HCPCS Level II J7607: Levalbuterol Inhalation Solution, Compounded 0.5 mg
HCPCS Level II code J7607 denotes a compounded concentrated levalbuterol inhalation solution, 0.5 mg, prepared for administration through durable medical equipment such as a nebulizer. The code captures a specific pharmaceutical formulation used in bronchodilator therapy for respiratory conditions where a compounded concentration is required. Nationally, accurate coding for compounded inhalation products affects coverage decisions, DME coordination, and billing consistency for outpatient and home-based respiratory care.
Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the clinical context for J7607, the typical sites of service (home health and outpatient respiratory clinics), and the implications for billing and DME administration. The publication outlines common modifiers and payer considerations, summarizes benchmarking and reimbursement context where available, and highlights policy or coding guidance relevant to compounded inhalation drug products.
This summary provides clinicians, billing professionals, and policy analysts with the essential information to identify when J7607 applies, understand its role in respiratory therapy workflows, and locate further details on payer-specific coverage and billing practices. Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.
Billing Code Overview
HCPCS Level II code J7607 represents levalbuterol inhalation solution, compounded product, concentrated form, 0.5 mg, intended for administration through durable medical equipment (DME). This code describes a compounded bronchodilator solution used for inhalation therapy when a concentrated formulation is required for nebulization via DME.
Service Type: Drug administration via durable medical equipment (nebulizer inhalation solution)
Typical Site of Service: Home health or outpatient settings where DME nebulizers are used, including skilled home infusion or respiratory therapy delivered in the patient’s residence or outpatient infusion/respiratory clinics.
Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult or pediatric patient with acute bronchospasm due to asthma, chronic obstructive pulmonary disease (COPD) exacerbation, or reactive airway disease who requires inhaled short-acting beta-agonist therapy delivered via a durable medical equipment nebulizer. The medication J7607 describes a compounded concentrated inhalation solution of levalbuterol 0.5 mg administered through DME. In practice the patient presents to an outpatient infusion or pulmonary clinic, emergency department observation unit, or at home using DME nebulizer support. The clinical workflow: a clinician evaluates the patient, documents the indication (for example, worsening wheeze and increased work of breathing), orders the compounded levalbuterol solution to be prepared by the pharmacy or compounding service, and the medication is billed as J7607 when dispensed and administered through the DME nebulizer. Nursing or respiratory therapy documents administration parameters (dose, time, route via nebulizer), response to therapy (improvement in auscultatory findings, peak expiratory flow), and any adverse events. For home use, DME suppliers coordinate training on nebulizer use and supply concentrations per the prescription; claims may include the appropriate place of service and applicable modifiers for payer adjudication.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 |